Heart Failure, ICD, Lead, Ventricular Arrythmia
Conditions
Brief summary
The primary objective of this study is to assess the safety and key electrical performance of the INVICTA leads equipped with DF4 connector: ACTIVE fixation type models (single and dual coil: INVICTA 1CR, INVICTA 2CR)
Detailed description
APOLLO study is a pre-market approval (INVICTA leads - devices under investigation - are not CE marked), interventional, prospective, longitudinal, international (European), multicenter, single arm study. The devices under investigation, the INVICTA defibrillation leads, are new quadripolar leads, to be used with Implantable Cardiac Defibrillators and Cardiac Resynchronization Therapy Defibrillators (ICD/CRT-D). This clinical study intends to demonstrate safety and electrical performances of the INVICTA leads among the different models: active fixation either single coil (model 1CR) or dual coil (model 2CR)leads models. The clinical data will be used to support the application to CE marking of INVICTA leads. The primary endpoints will be evaluated at 3 months post-implantation; secondary endpoints will be evaluated up to 2 years post-implantation. A total number of 445 patients will be enrolled in the study, in up to 60 centers in Europe. The follow-up visits are scheduled at hospital discharge, at 1 month, at 3 months, at 6 months, at 12 months, at 18 months and at 24 months, post-implant
Interventions
DEVICEINVICTA lead
The implant or the attempt to implant an INVICTA lead
Sponsors
MicroPort CRM
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Intervention model description
INVICTA lead
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
1. Any patient presenting an ICD or CRT-D indication as detailed in the latest ESC guidelines 2. Scheduled for a de-novo implant of an ICD (VR, DR) or CRT-D, manufactured by MicroPort CRM and equipped with a DF4 connector 3. Signed and dated informed consent
Exclusion criteria
1. Tricuspid valvular disease or any type of tricuspid replacement heart valve (mechanical or tissue) 2. Transient tachyarrhythmias due to reversible causes (such as drug intoxication, electrolyte imbalance, sepsis, hypoxia or other factors as myocardial infarction or electric shock) 3. Contraindication to a maximum single dose of 330 µg dexamethasone sodium phosphate (DSP) 4. Active myocarditis 5. Previous implant of pacemaker, ICD or CRT-D device and leads 6. Currently enrolled or planning to participate in a potentially confounding drug or device trial during the course of this study 7. Incapacitated subject or under guardianship, inability to understand the purpose of the study, or to meet follow-up visits at the implanting centre as defined in the investigational plan 8. Minor subjects 9. Pre-menopausal women 10. Drug addiction or abuse 11. Life expectancy less than 1 year
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| 1.Freedom from INVICTA lead-related complications 1.Freedom from INVICTA lead-related complications [Time Frame: 90 days | 90 days | Freedom from INVICTA lead-related complications as assessed by an independent events adjudicator and defined as any INVICTA lead-related serious adverse device effect (SADE) that resulted in patient death or required an additional invasive intervention |
| 2.INVICTA lead electrical performance at 3 months | 3 months | Right Ventricular (RV) pacing threshold (V) of the INVICTA lead, measured by the implanted ICD/CRT-D with 0.5 ms pulse width |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Serious Adverse Events up to 24 months | 24 months | Report of SAEs occurred up to 24 months post-implantation |
| Daily INVICTA autothreshold values (V) | 1 month | Assessment of Daily INVICTA autothreshold values (V) |
| .INVICTA lead handling assessment | At implant (day 0) | Summary of the investigators' opinion about INVICTA handling at implant |
| INVICTA lead implant success rate | At implant (day 0) | % of enrolled patients successfully implanted with an INVICTA lead |
| INVICTA lead pacing threshold | 24 months | RV lead pacing threshold amplitude (V), measured by the implanted ICD/CRT-D with 0.5 ms pulse width |
| INVICTA lead impedances | 24 months | RV lead pacing impedance (Ohm) and defibrillation coil impedance (Ohm), measured by the implanted ICD/CRT-D |
| INVICTA sensing threshold | 24 months | RV lead endocardial R wave amplitude (mV), measured by the implanted ICD/CRT-D |
| Percentage of the shocks that successfully terminate a ventricular arrhythmia episode | 24 months | Percentage of endocardial shock therapies that successfully terminate ventricular arrhythmia episodes, calculated as the proportion of successful shocks on the total number of shocks delivered during defibrillation testing or spontaneous ventricular arrhythmias |
| Acute INVICTA lead complications | 30 days | Assessment of Acute INVICTA lead complications |
| Chronic INVICTA lead complications | > 30 days | Assessment of Chronic INVICTA lead complications |
Other
| Measure | Time frame | Description |
|---|---|---|
| Chronic complication rates as a function of the lead position | > 30 days | Chronic complication rates as a function of the lead position (apical vs septal |
| Electrical performances as a function of the lead position | 24 months | Electrical performances as a function of the lead position (apical vs septal) |
| Acute complication rates as a function of the lead position | < 30 days | Acute complication rates as a function of the lead position (apical vs septal) |
Countries
Austria, France, Germany, Italy, Netherlands, Portugal, Spain, United Kingdom
Outcome results
None listed